Insilico Medicine's stock plummeted 5.16% during Tuesday's intraday session, extending a recent decline.

The slide is attributed to continued profit-taking following a significant rally driven by multiple positive developments, including breakthroughs in its AI drug discovery platform, strategic partnerships, and key research disclosures. Despite the company's recent announcement of a new AI-driven preclinical candidate, selling pressure has persisted. The move also sharply diverges from the broader Life Sciences Tools and Services sector, which saw strong gains from several peers on the same day.